Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2014

Open Access 01-02-2014 | Research article

Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR/HLA-DR1) humanized model of arthritis

Authors: Bo Tang, Seunghyun Kim, Sarah Hammond, David L Cullins, David D Brand, Edward F Rosloniec, John M Stuart, Arnold E Postlethwaite, Andrew H Kang, Linda K Myers

Published in: Arthritis Research & Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

T cells orchestrate joint inflammation in rheumatoid arthritis (RA), yet they are difficult to study due to the small numbers of antigen-specific cells. The goal of this study was to characterize a new humanized model of autoimmune arthritis and to describe the phenotypic and functional changes that occur in autoimmune T cells following the induction of pathological events.

Methods

We developed a double transgenic mouse containing both the HLA-DR1 transgene and an HLA-DR1-restricted collagen-specific TCR in order to obtain large numbers of antigen-specific T cells that can be used for immunologic studies.

Results

In vitro, CII-specific T cells from this mouse proliferated vigorously in response to the CII immunodominant peptide A2 and the cells altered their phenotype to become predominately CD62Llow and CD44high “activated” T cells. The response was accompanied by the production of Th1, Th2, and Th17-type cytokines. Following immunization with bovine CII/CFA, these mice develop an accelerated arthritis compared to single transgenic HLA-DR1 mice. On the other hand, when the mice were treated orally with the analog peptide A12, (a suppressive analog of collagen we have previously described), arthritis was significantly suppressed, despite the fact that >90% of the CD4+ T cells express the TCR Tg. In GALT tissues taken from the A12-treated mice, IL-2, IFN-γ, and IL-17 production to the autoimmune collagen determinant dropped while high levels of IL-10 and IL-4 were produced.

Conclusions

We have developed a humanized model of autoimmune arthritis that will be useful for the study of T cell directed therapies as well as T cell mediated mechanisms of autoimmune diseases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Huber BT, Kappler J, Hafler DA: Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci USA. 2000, 97: 11433-11438. 10.1073/pnas.190335897.CrossRefPubMedPubMedCentral Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Huber BT, Kappler J, Hafler DA: Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci USA. 2000, 97: 11433-11438. 10.1073/pnas.190335897.CrossRefPubMedPubMedCentral
2.
go back to reference Oh S, Aitken M, Simons DM, Basehoar A, Garcia V, Kropf E, Caton AJ: Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis. J Immunol. 2012, 188: 4171-4180. 10.4049/jimmunol.1103598.CrossRefPubMedPubMedCentral Oh S, Aitken M, Simons DM, Basehoar A, Garcia V, Kropf E, Caton AJ: Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis. J Immunol. 2012, 188: 4171-4180. 10.4049/jimmunol.1103598.CrossRefPubMedPubMedCentral
3.
go back to reference Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD: Collagen-induced arthritis. Curr Protoc Immunol. 2010, 15: 11-25. Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD: Collagen-induced arthritis. Curr Protoc Immunol. 2010, 15: 11-25.
4.
go back to reference Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, Woods A, Altmann DM, Stuart JM, Kang AH: An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med. 1997, 185: 1113-1122. 10.1084/jem.185.6.1113.CrossRefPubMedPubMedCentral Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, Woods A, Altmann DM, Stuart JM, Kang AH: An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med. 1997, 185: 1113-1122. 10.1084/jem.185.6.1113.CrossRefPubMedPubMedCentral
5.
go back to reference Kouskoff V, Signorelli K, Benoist C, Mathis D: Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods. 1995, 180: 273-280. 10.1016/0022-1759(95)00002-R.CrossRefPubMed Kouskoff V, Signorelli K, Benoist C, Mathis D: Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods. 1995, 180: 273-280. 10.1016/0022-1759(95)00002-R.CrossRefPubMed
6.
go back to reference He X, Rosloniec EF, Myers LK, McColgan WL, Gumanovskaya M, Kang AH, Stuart JM: T cell receptors recognizing type II collagen in HLA-DR-transgenic mice characterized by highly restricted V beta usage. Arthritis Rheum. 2004, 50: 1996-2004. 10.1002/art.20289.CrossRefPubMed He X, Rosloniec EF, Myers LK, McColgan WL, Gumanovskaya M, Kang AH, Stuart JM: T cell receptors recognizing type II collagen in HLA-DR-transgenic mice characterized by highly restricted V beta usage. Arthritis Rheum. 2004, 50: 1996-2004. 10.1002/art.20289.CrossRefPubMed
7.
go back to reference Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF: Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol. 2005, 174: 3978-3985.CrossRefPubMed Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF: Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol. 2005, 174: 3978-3985.CrossRefPubMed
8.
go back to reference Rosloniec EF, Ivey RA, Whittington KB, Kang AH, Park HW: Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol. 2006, 177: 3884-3892.CrossRefPubMed Rosloniec EF, Ivey RA, Whittington KB, Kang AH, Park HW: Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol. 2006, 177: 3884-3892.CrossRefPubMed
9.
go back to reference Myers LK, Cullins DL, Brand DD, Kleinau S, Stuart JM, Kang AH: T cells stimulated with an analog peptide of type II collagen require the Fc receptor gamma-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice. Arthritis Rheum. 2011, 63: 2661-2670. 10.1002/art.30454.CrossRefPubMedPubMedCentral Myers LK, Cullins DL, Brand DD, Kleinau S, Stuart JM, Kang AH: T cells stimulated with an analog peptide of type II collagen require the Fc receptor gamma-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice. Arthritis Rheum. 2011, 63: 2661-2670. 10.1002/art.30454.CrossRefPubMedPubMedCentral
10.
go back to reference Vincent TL, Williams RO, Maciewicz R, Silman A, Garside P: Mapping pathogenesis of arthritis through small animal models. Rheumatology (Oxford). 2012, 51: 1931-1941. 10.1093/rheumatology/kes035.CrossRef Vincent TL, Williams RO, Maciewicz R, Silman A, Garside P: Mapping pathogenesis of arthritis through small animal models. Rheumatology (Oxford). 2012, 51: 1931-1941. 10.1093/rheumatology/kes035.CrossRef
11.
go back to reference Brand DD, Kang AH, Rosloniec EF: Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003, 25: 3-18. 10.1007/s00281-003-0127-1.CrossRefPubMed Brand DD, Kang AH, Rosloniec EF: Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003, 25: 3-18. 10.1007/s00281-003-0127-1.CrossRefPubMed
12.
go back to reference Choy E: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012, 51: v3-v11. 10.1093/rheumatology/kes113.CrossRef Choy E: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012, 51: v3-v11. 10.1093/rheumatology/kes113.CrossRef
13.
go back to reference Salliot C, Dawidowicz K, Lukas C, Guedj M, Paccard C, Benessiano J, Dougados M, Nicaise P, Meyer O, Dieude P: PTPN22 R620W genotype-phenotype correlation analysis and gene-environment interaction study in early rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford). 2011, 50: 1802-1808. 10.1093/rheumatology/ker224.CrossRef Salliot C, Dawidowicz K, Lukas C, Guedj M, Paccard C, Benessiano J, Dougados M, Nicaise P, Meyer O, Dieude P: PTPN22 R620W genotype-phenotype correlation analysis and gene-environment interaction study in early rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford). 2011, 50: 1802-1808. 10.1093/rheumatology/ker224.CrossRef
14.
go back to reference Chang WC, Woon PY, Wei JC, Chang CM, Hsu YW, Guo YC, Hwang DY, Kochi Y, Yen JH: A Single-nucleotide Polymorphism of CCR6 (rs3093024) is associated with susceptibility to rheumatoid arthritis but not ankylosing spondylitis, in a Taiwanese population. J Rheumatol. 2012, 39: 1765-10.3899/jrheum.120040.CrossRefPubMed Chang WC, Woon PY, Wei JC, Chang CM, Hsu YW, Guo YC, Hwang DY, Kochi Y, Yen JH: A Single-nucleotide Polymorphism of CCR6 (rs3093024) is associated with susceptibility to rheumatoid arthritis but not ankylosing spondylitis, in a Taiwanese population. J Rheumatol. 2012, 39: 1765-10.3899/jrheum.120040.CrossRefPubMed
15.
go back to reference Iannone F, Lapadula G: The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl. 2012, 89: 100-102. 10.3899/jrheum.120257.CrossRefPubMed Iannone F, Lapadula G: The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl. 2012, 89: 100-102. 10.3899/jrheum.120257.CrossRefPubMed
16.
go back to reference Kitagishi Y, Kobayashi M, Yamashina Y, Matsuda S: Elucidating the regulation of T cell subsets (Review). Int J Mol Med. 2012, 30: 1255-1260.PubMed Kitagishi Y, Kobayashi M, Yamashina Y, Matsuda S: Elucidating the regulation of T cell subsets (Review). Int J Mol Med. 2012, 30: 1255-1260.PubMed
17.
go back to reference Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL: Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol. 1995, 147: 1193-1199.PubMedPubMedCentral Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL: Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol. 1995, 147: 1193-1199.PubMedPubMedCentral
18.
go back to reference Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH: An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci. 2004, 327: 212-216. 10.1097/00000441-200404000-00007.CrossRefPubMed Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH: An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci. 2004, 327: 212-216. 10.1097/00000441-200404000-00007.CrossRefPubMed
19.
go back to reference Peron JP, de Oliveira AP, Rizzo LV: It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response. Autoimmun Rev. 2009, 9: 1-4. 10.1016/j.autrev.2009.02.024.CrossRefPubMed Peron JP, de Oliveira AP, Rizzo LV: It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response. Autoimmun Rev. 2009, 9: 1-4. 10.1016/j.autrev.2009.02.024.CrossRefPubMed
20.
go back to reference Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, Morse HC, Nussenblatt RB, Caspi RR: IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol. 1999, 162: 2613-2622.PubMed Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, Morse HC, Nussenblatt RB, Caspi RR: IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol. 1999, 162: 2613-2622.PubMed
21.
go back to reference Zhu H, Lei X, Liu Q, Wang Y: Interleukin-10–1082A/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. Cytokine. 2012, 61: 146-153.CrossRefPubMed Zhu H, Lei X, Liu Q, Wang Y: Interleukin-10–1082A/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. Cytokine. 2012, 61: 146-153.CrossRefPubMed
22.
go back to reference Gong Y, Wang Z, Liang Z, Duan H, Ouyang L, Yu Q, Xu Z, Shen G, Weng X, Wu X: Soluble MOG35-55/I-A(b) Dimers Ameliorate Experimental Autoimmune Encephalomyelitis by Reducing Encephalitogenic T Cells. PLoS One. 2012, 7: e47435-10.1371/journal.pone.0047435.CrossRefPubMedPubMedCentral Gong Y, Wang Z, Liang Z, Duan H, Ouyang L, Yu Q, Xu Z, Shen G, Weng X, Wu X: Soluble MOG35-55/I-A(b) Dimers Ameliorate Experimental Autoimmune Encephalomyelitis by Reducing Encephalitogenic T Cells. PLoS One. 2012, 7: e47435-10.1371/journal.pone.0047435.CrossRefPubMedPubMedCentral
23.
go back to reference Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM study investigators: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012, 367: 1087-1097. 10.1056/NEJMoa1206328.CrossRefPubMed Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM study investigators: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012, 367: 1087-1097. 10.1056/NEJMoa1206328.CrossRefPubMed
24.
go back to reference Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995, 45: 1268-1276. 10.1212/WNL.45.7.1268.CrossRefPubMed Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995, 45: 1268-1276. 10.1212/WNL.45.7.1268.CrossRefPubMed
25.
go back to reference Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Volmer T, Weiner LP, Wolinsky JS: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998, 50: 701-708. 10.1212/WNL.50.3.701.CrossRefPubMed Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Volmer T, Weiner LP, Wolinsky JS: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998, 50: 701-708. 10.1212/WNL.50.3.701.CrossRefPubMed
26.
go back to reference Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, Group FS: Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011, 69: 75-82. 10.1002/ana.22316.CrossRefPubMed Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, Group FS: Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011, 69: 75-82. 10.1002/ana.22316.CrossRefPubMed
27.
go back to reference Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, CombiRx I: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013, 73: 327-340. 10.1002/ana.23863.CrossRefPubMedPubMedCentral Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, CombiRx I: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013, 73: 327-340. 10.1002/ana.23863.CrossRefPubMedPubMedCentral
28.
go back to reference Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pasto L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tolar MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP: Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012, 12: 124-10.1186/1471-2377-12-124.CrossRefPubMedPubMedCentral Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pasto L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tolar MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP: Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012, 12: 124-10.1186/1471-2377-12-124.CrossRefPubMedPubMedCentral
29.
go back to reference Yoshino S, Quattrocchi E, Weiner HL: Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. Arthritis Rheum. 1995, 38: 1092-1096. 10.1002/art.1780380811.CrossRefPubMed Yoshino S, Quattrocchi E, Weiner HL: Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. Arthritis Rheum. 1995, 38: 1092-1096. 10.1002/art.1780380811.CrossRefPubMed
30.
go back to reference Bielekova B, Martin R: Antigen-specific immunomodulation via altered peptide ligands. J Mol Med. 2001, 79: 552-565. 10.1007/s001090100259.CrossRefPubMed Bielekova B, Martin R: Antigen-specific immunomodulation via altered peptide ligands. J Mol Med. 2001, 79: 552-565. 10.1007/s001090100259.CrossRefPubMed
31.
Metadata
Title
Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR/HLA-DR1) humanized model of arthritis
Authors
Bo Tang
Seunghyun Kim
Sarah Hammond
David L Cullins
David D Brand
Edward F Rosloniec
John M Stuart
Arnold E Postlethwaite
Andrew H Kang
Linda K Myers
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4433

Other articles of this Issue 1/2014

Arthritis Research & Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.